




S1 Fig. Infecting cells at with VSV $\Delta$ G-BHLD at a higher MOI does not increase entry to an appreciable extent. Receptor null (B78H1 and CHO-K1) and receptor bearing cells (C10, CHO-HVEM, HeLa, Vero, HaCaT, and SH-SY5Y) were infected at MOI =1 (red) or MOI = 10 (purple). Entry efficiency was assessed by flow cytometry at 6 hours post infection.




S2 Fig. Increased amounts of surface nectin-1 or HVEM do not increase VSV $\Delta$ G-BHLD entry. CHO-K1 (receptor-null) cells were transfected with increasing amounts of plasmids encoding nectin-1 (pBG38) (A) or HVEM (pSC386) (B). Surface expression was analyzed by flow cytometry 24 hours post transfection. C) Cells transfected with nectin-1 or HVEM were infected with VSV $\Delta$ G-BHLD at MOI = 1. Entry efficiency was assessed at 6 hours post infection by flow cytometry. In each panel, receptor-bearing stable cell line data (CHO-nectin-1 and CHO-HVEM) were inserted as points of comparison.




S3 Fig. VSV $\Delta$ G-G and VSV $\Delta$ G-PIV5 differ in their dependence on dynamin for entry. C10 (A and B) and CHO-HVEM (C and D) cells were pretreated with dynamin inhibitors Dynasore (80  $\mu$ M), Dyngo-4a (25  $\mu$ M), or MiTMAB (5  $\mu$ M) and infected with VSV $\Delta$ G-G or VSV $\Delta$ G-PIV5 at a MOI of 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. CHO-HVEM cells treated with Dyngo-4a or MiTMAB used the same DMSO control as indicated by the same bar graph appearing twice each in panels C and D. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = \*; p < 0.01 = \*\*; p < 0.001 = \*\*\*).




S4 Fig. VSV $\Delta$ G-G entry does not require cholesterol whereas VSV $\Delta$ G-PIV5 entry requires cholesterol in a cell-type-dependent manner. C10 (A and B) and CHO-HVEM (C and D) cells were pretreated with a cholesterolremoval drug methyl-β-cyclodextran, MβCD (5 mM) and infected with  $VSV\Delta G$ -G or  $VSV\Delta G$ -PIV5 at a MOI of 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. (E) CHO-HVEM cells were transfected with a caveolin-1 siRNA (cav-1) or a scrambled control siRNA (scr) (both 50 pm) and infected with VSV $\Delta$ G-G or VSV $\Delta$ G-PIV5 at a MOI of 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05= \*; p < 0.01 = \*\*; p < 0.001 = \*\*\*). F) C10 and CHO-HVEM cells were treated with either a solvent control ( $H_2O/EtOH$ ) or methyl- $\beta$ -cyclodextrin (M $\beta$ CD), then incubated with cholera toxin subunit B labelled with Alexa Fluor 488. Confocal microscopy was performed on the solvent control and methyl-βcyclodextrin treated cells. Cells were fixed, counterstained with DAPI, and imaged by confocal microscopy. Scale bar =  $25 \mu m$ .




S5 Fig. VSV $\Delta$ G-BHLD does not co-localize with the fluid-phase marker 70 kDa dextran in C10 cells. C10 cells were incubated with 1 mg/ml of rhodamine-B labelled 70 kDa dextran and VSV $\Delta$ G-BHLD (MOI = 1) for one hour at 4°C. Cells were then shifted to 37 °C for 20 minutes. Cells were fixed, counterstained with DAPI, and imaged by confocal microscopy. gB was detected by immunofluorescence using the rabbit pAb R68 and anti-rabbit IgG conjugated to FITC. Green = gB (marker for VSV $\Delta$ G-BHLD particles); Red = 70 kDa dextran. Scale bar = 25  $\mu$ m.



S6 Fig. VSV $\Delta$ G-BHLD, in large, does not co-localized with the fluid-phase marker, 70 kDa dextran, in CHO-HVEM cells. CHO-HVEM cells were incubated with 1 mg/ml of rhodamine-B labelled 70 kDa dextran and VSV $\Delta$ G-BHLD (MOI = 1) for one hour at 4°C. Cells were then shifted to 37°C for 20 minutes. Cells were fixed, counterstained with DAPI, and imaged by confocal microscopy. gB was detected by immunofluorescence using the rabbit pAb R68 and anti-rabbit IgG conjugated to FITC. Green = gB (marker for VSV $\Delta$ G-BHLD particles); Red = 70 kDa dextran. Scale bar = 25  $\mu$ m.



S7 Fig. VSV $\Delta$ G-G and VSV $\Delta$ G-PIV5 entry does not require macropinocytosis. C10 (A and B) and CHO-HVEM (C and D) cells were pretreated with macropinocytosis inhibitors cytochalasin D (2  $\mu$ M), EIPA (25  $\mu$ M), or NSC23766 (200  $\mu$ M) and infected with VSV $\Delta$ G-G or VSV $\Delta$ G-PIV5 at a MOI of 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = \*; p < 0.01 = \*\*; p < 0.001 = \*\*\*).



S8 Fig. VSV $\Delta$ G-G but not VSV $\Delta$ G-PIV5 entry requires endosomal acidification. C10 (A and B) and CHO-HVEM (C and D) cells were pretreated with inhibitors of endosomal acidification BFLA (100 nM), NH<sub>4</sub>Cl (50 mM), or monensin (15  $\mu$ M) and infected with VSV $\Delta$ G-G or VSV $\Delta$ G-PIV5 at MOI = 1. Infectivity was quantitated by flow cytometry at 6 hours post infection. Significance was calculated using a two-tailed Student's T-test with Welch's correction (p < 0.05 = \*; p < 0.01 = \*\*; p < 0.001 = \*\*\*).